Aviscumine (ME-503)-Skin Reaction as significant Factor for its Efficacy Expanded Evaluation of the Results from the Phase II Trial NCT00658437
Trefzer, Uwe, Gutzmer, Ralf, Wilhelm, Tabea, Schenck, Florian, Kahler, Katharina C, Jacobi, Volkmar, Witthohn, Klaus, Lentzen, Hans, Mohr, PeterVolume:
3
Year:
2017
Language:
english
Journal:
Immunotherapy Open Access
DOI:
10.4172/2471-9552.1000135
File:
PDF, 393 KB
english, 2017